Travere Therapeutics (TVTX) Cash from Operations Growth (5y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.80% |
| Dec 31, 2025 | 44.84% |
| Sep 30, 2025 | 16.28% |
| Jun 30, 2025 | 22.62% |
| Mar 31, 2025 | -7.67% |
| Dec 31, 2024 | -44.47% |
| Sep 30, 2024 | -24.66% |
| Jun 30, 2024 | -16.12% |
| Mar 31, 2024 | -42.14% |
| Dec 31, 2023 | -78.37% |
| Sep 30, 2023 | -95.23% |
| Jun 30, 2023 | -79.73% |
| Mar 31, 2023 | -46.27% |
| Dec 31, 2022 | -145.85% |
| Sep 30, 2022 | -75.91% |
| Jun 30, 2022 | -54.25% |
| Mar 31, 2022 | -74.62% |
| Dec 31, 2021 | -59.74% |
| Sep 30, 2021 | 47.27% |
| Jun 30, 2021 | 10.24% |
| Mar 31, 2021 | -49.31% |
| Dec 31, 2020 | -31.32% |
| Sep 30, 2020 | 55.57% |
| Jun 30, 2020 | -22.91% |
| Mar 31, 2020 | -34.62% |
| Dec 31, 2019 | 13.16% |
| Sep 30, 2019 | 1.85% |
| Jun 30, 2019 | -10.79% |
| Mar 31, 2019 | -15.88% |
| Dec 31, 2018 | 15.75% |
| Mar 31, 2018 | -26.33% |